BioSpace News Archive

Promontory Therapeutics Inc. has completed enrollment of its Phase 2 clinical trial of lead therapeutic candidate, PT-112, reaching its target enrollment of 109 patients with late-line metastatic castration-resistant prostate cancer (mCRPC) (ClinicalTrials.gov Identifier: NCT02266745).

UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) to 12 new employees in connection with their employment with UroGen.

Senseonics Holdings, Inc. Announces Data From the Eversense ® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes.

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

Agendia®, Inc., announced it will share new data from the ongoing prospective, observational FLEX Trial in two poster presentations at the 41st Annual Miami Breast Cancer Conference, taking place March 7 – 10th, 2024.

Exagen Inc. today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024.

Biofrontera Inc. today announced that it will report financial results for the three and 12 months ended December 31, 2023 on Friday, March 15, 2024.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 (KT-621) and TYK2 (KT-294) are being presented in the poster session at the American Academy of Dermatology’s Annual Meeting in San Diego, California.

U.S. veterans are at a higher risk of developing melanoma, one of the deadliest forms of skin cancer, likely due in part to the occupational hazards associated with active duty in countries near the equator where ultraviolet levels are higher.

bioAffinity Technologies, Inc. announced it has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement at a combined purchase price of $1.5625 per common share.